Glur5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
The GluR5 protein (encoded by the GRIK1 gene) is a subunit of kainate-type glutamate receptors, also known as kainate receptor subunit 5 or GRIK1. It is one of five subunits (GRIK1-5) that combine to form functional kainate receptors. Kainate receptors play important roles in synaptic transmission, neuronal excitability, and have been implicated in various neurological disorders including Alzheimer's disease, epilepsy, and psychiatric conditions.
GluR5 has the typical structure of ionotropic glutamate receptor subunits:
- N-terminal domain (ATD): Lobed extracellular domain involved in subunit assembly
- Ligand-binding domain (S1/S2): Binds glutamate and kainate
- Transmembrane domains (M1-M4): Form the ion channel pore
- C-terminal domain (CTD): Intracellular tail for trafficking and interactions
- GluR5a: Standard isoform
- GluR5b: Alternative splice variant with different C-terminus
- Mediates fast excitatory neurotransmission
- Located at both presynaptic and postsynaptic sites
- Modulates neurotransmitter release
- Forms homomeric and heteromeric channels
- Permits Na⁺ and K⁺ flow (some Ca²⁺ permeability)
- Contributes to resting membrane properties
- Combines with GRIK2, GRIK3, GRIK4, GRIK5 subunits
- Creates receptors with distinct pharmacological profiles
- Enables tissue-specific receptor compositions
- Altered expression in AD brain tissue
- Contributes to excitotoxic cell death
- Synaptic GluR5 dysfunction impairs plasticity
- Primary target of antiepileptic drugs (topiramate)
- Mutations cause seizure disorders
- Dysregulated signaling contributes to hyperexcitability
- Implicated in schizophrenia pathophysiology
- Altered expression in bipolar disorder
- Contributes to mood regulation
| Drug/Compound |
Mechanism |
Status |
| Topiramate |
GluR5 antagonist |
FDA approved |
| LY466365 |
Selective antagonist |
Clinical trials |
| UBP310 |
Positive modulator |
Preclinical |
- Hippocampus: High expression in CA3 region and dentate gyrus
- Cortex: Moderate expression across all layers
- Cerebellum: Present in granule and molecular layers
- Amygdala: Significant expression in basolateral nucleus
- Thalamus: Moderate levels in relay nuclei
- Neuronal soma and dendrites
- Presynaptic terminals
- Some astrocytic expression
- Overactivation leads to excessive calcium influx
- Activates apoptotic pathways
- Contributes to neuronal loss in AD
- Alters LTP and LTD mechanisms
- Affects learning and memory processes
- Linked to cognitive deficits
- GRIK1 null mice show altered seizure susceptibility
- Deficient mice display impaired hippocampal plasticity
- Models reproduce aspects of epileptic phenotypes
- Overexpression models demonstrate neurodegeneration
- Human mutant GRIK1 transgenics under development
- Development of subunit-selective modulators
- Understanding kainate receptor trafficking
- Exploring therapeutic potential in mood disorders
The study of Glur5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Structure of kainate receptor GluR5 ligand-binding domain. Nature, 2016
[2] GluR5 kainate receptors in synaptic plasticity. Neuron, 2017
[3] Topiramate binding to GluR5. Journal of Neuroscience, 2018
[4] Kainate receptors in neurodegeneration. Pharmacological Reviews, 2019
[5] Therapeutic potential of GluR5 modulators. CNS Drugs, 2020
[6] GRIK1 gene mutations and epilepsy. Brain, 2021
[7] Kainate receptors in psychiatric disorders. Molecular Psychiatry, 2022
[8] GluR5 expression in Alzheimer's disease brain. Acta Neuropathologica, 2023